NORTHAMPTON, MA / ACCESS Newswire / April 1, 2025 / In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe ...
PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...
Barchart on MSN14h
These 2 Buy-Rated Dividend Stocks Could Be Next in Line for a Trump Tariff Selloff. Should You Jump Ship Now?President Donald Trump recently proposed tariffs on pharmaceutical imports from countries like Ireland and India, both key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback